// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Current practices of Ultrasound for assessment of Crohn’s Disease in the UK

Leighton, P - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

The impact of an educational and networking event on nurses caring for Inflammatory Bowel Disease (IBD) paediatric patients receiving biologic therapy

Gil Zaragozano, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Systematic Review: The role of psychological stress in Inflammatory Bowel Disease

Black, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Clinical service delivery implications of the Covid-19 pandemic on people with inflammatory bowel disease: a qualitative study

Kemp, K - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

‘Same storm, different boat’… Exploring the impact of the COVID-19 pandemic on patients with Inflammatory Bowel Disease, with or without shielding: a qualitative study

Kemp, K - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

Safety of extended blood monitoring for adult Inflammatory Bowel Disease (IBD) patients on oral azathioprine during the COVID-19 pandemic: a single-centre audit

AL-HASANI, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Oraprine

A Cost Benefit Analysis of Different Minimal Access Donor Nephrectomy Techniques Performed at a Busy Transplant Centre

H. Sharma - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Analyzing the Impact of Covid-19 in the Hospitalized Cohort of Liver Transplant Recipients: An Early Systematic Review and Meta-Analysis

J. Kumar - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Angiotensin II Type-1 Receptor Antibodies are Associated with Inferior Renal Allograft Survival

P. Martin - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Angiotensin II

Anti-HLA-DP Antibodies Positive – A Retrospective Review of Outcomes in Renal Transplantation- Single Centre Experience

O. Piscoran - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Centre Variation in Emergency Hospital Readmissions Following Renal Transplantation in England

J. Peracha - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisation of Distinct Graft Infiltrates Following Cellular Therapy in Kidney Transplant Recipients

M. O. Brook - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of Defibrotide on Kidney Ischemia Reperfusion Injury in a Preclinical Renal Transplant Model

P. Pine - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemia-reperfusion injury

Defibrotide

Effect of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Individual Level and Within Twenty Five Race/ethnic Groups

H. C. Copley - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Has the Proportional Rise in Deceased Organ Donation Rate Over Last 5 Years Been Optimal? A Data-based, Forecasting Model Analysis of UNOS/NHSBT UK Donor Data

H. Sharma - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Has the Proportional Rise in Deceased Organ Donation Rate Over Last 5 Years Been Optimal? Data-based, Forecasting Model Analysis of UNOS/NHSBT UK Donor Data

H. Sharma - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Hypoperfusion Warm Ischaemia Time in Renal Transplants from Donors After Circulatory Death

I. D. Kostakis - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Delayed graft function

N/A

IL-10 Signaling in T Cells Modulates Costimulation-independent Activation and is Essential for Transplant Tolerance Induction

M. Iglesias Lozano - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interleukin-10

Increased Deceased Organ Donation Rates Among Racial and Ethnic Minorities: Not Exactly. A UNOS/NHSBT UK Donor Data Analysis Over the Last Five Years

H. Sharma - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Kidney Transplantation from Marginal Donors: An Increased Risk of Urinary Complication. Study from 10279 Patients

B. Mesnard - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved